Drug reference directory
Drug reference

meglumine antimoniate

Antileishmanial agent

Antileishmanial agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
8 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 8 →
  • AmitriptylineSevereTextbookHarrison 22e · p1740
  • AmoxapineSevereTextbookHarrison 22e · p1740
  • ClomipramineSevereTextbookHarrison 22e · p1740
  • DesipramineSevereTextbookHarrison 22e · p1740

Mechanism

Not yet extracted

Pharmacokinetics

Half-life
<2 h (first phase); nearly 36 h (terminal phase)

Side effects

Common
arthralgiasmyalgiaspancreatitisecg changes (qt prolongation, t-wave flattening or inversion)

Drug interactions

Amitriptyline
Severe
Textbook

Increased cardiotoxicity (e.g., QT prolongation).

Source: Harrison 22e · p1740

Amoxapine
Severe
Textbook

Increased cardiotoxicity (e.g., QT prolongation).

Source: Harrison 22e · p1740

Clomipramine
Severe
Textbook

Increased cardiotoxicity (e.g., QT prolongation).

Source: Harrison 22e · p1740

Desipramine
Severe
Textbook

Increased cardiotoxicity (e.g., QT prolongation).

Source: Harrison 22e · p1740

Doxepin
Severe
Textbook

Increased cardiotoxicity (e.g., QT prolongation).

Source: Harrison 22e · p1740

Imipramine
Severe
Textbook

Increased cardiotoxicity (e.g., QT prolongation).

Source: Harrison 22e · p1740

Mirtazapine
Severe
Textbook

Increased cardiotoxicity (e.g., QT prolongation).

Source: Harrison 22e · p1740

Nortriptyline
Severe
Textbook

Increased cardiotoxicity (e.g., QT prolongation).

Source: Harrison 22e · p1740

Other Unclassified drugs

Ask House about meglumine antimoniate

Continue into a citation-backed clinical answer with the drug context already attached.

Textbook-sourced·Sources: Harrison 22e·Updated: 2026-05-10